Eli Lilly's New Migraine Medicine
Eli Lilly & Co. (LLY) reported it's wildly successful data from a Phase 3 trial of it's migraine medicine called Lasmiditan. Migraines are not an uncommon, debilitating occurrence. I, myself, went through a period when I was somewhat afflicted with the condition. In my experience there are three hallmarks of a migraine: head pain, a visual aura, and nausea. The aura is the strangest aspect of the symptoms. With me, it involved the interruption of a clear field of vision with what seemed like a waving visual range. This usually began in a small area of my visual field, and could spread to my whole vision before the migraine receded. Another symptom is nausea. When I would get a full-blown migraine, about half the time, it caused me to throw up. It seems odd that a headache and visual disturbance would cause that, but it does.
At the peak of my affliction, in high school and college, I only had about 4-8 migraines a year. But, when I got one, it generally shut me down for the whole day. The medicines I used back then usually only reduced the duration of the affliction.
The reader may find it interesting that once I started taking the tandem drugs: Zyprexa and Depakote, I no longer suffered any migraines. I discovered that Depakote, sold by AbbVie Inc. (ABBV), is known to have anti-migraine effects.
I suffered from a very mild form of migraine occurrence, so Depakote may not be appropriate for many of those with the condition.
I knew someone for a brief time, whom I worked with, who had chronic migraine headaches, suffering from a migraine about every other day. She definitely needed something a lot stronger than what I was on. Eli Lilly & Co.'s (LLY) migraine medicine may find it's market for her and some of the 30 million migraine afflicted adults in the U.S. still looking for a better solution. I hope Lasmiditan is a success and makes Eli Lilly a lot of money.
Paul Wharton
Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind